Lyophilised Reverse Transcriptase and Polymerase for Point‐of‐Care Diagnostics of SARS ‐ CoV ‐2
Microbial Biotechnology · 2025-07 · 18 (7)
DOI: 10.1111/1751-7915.70200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 24.07.2025. Verfasst von Natalie Mutter und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Diagnostics, Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Vienna, Austria. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Point-of-Care Testing, Nucleic Acid Amplification Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking, European Union's Horizon 2020 Research and Innovation Programme and EFPIA.
Abstract (Originalsprache)
Early diagnosis of pathogens is key to reducing their spreading and to preventing severe health risks. The COVID‐19 pandemic showed us the need for rapid point‐of‐care tests. Here, we describe the preparation of an amplification master mix for point‐of‐care diagnostics. Therefore, two off‐patent amplification enzymes were designed, expressed and purified. The preparation of the key components enables independence from delivery issues, manufacturer portfolio and product information's. For long‐term storage and cold‐free transport, our fabricated amplification mix was lyophilised. Finally, we applied our lyophilised master mix on an integrated point‐of‐care diagnostic system and could detect 10 copies/μL COVID‐19 RNA. The combination of stable, cold‐free reagents with the mobile and low‐cost device will allow molecular diagnostics of pathogens in a field or home setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Diagnostics, Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Vienna, Austria.
- Sustainable Thermal Energy Systems, Center for Energy, AIT Austrian Institute of Technology GmbH, Vienna, Austria.
- HP Health Solutions Germany GmbH, Planegg, Germany.
ORCID-Profile: Natalie Mutter, Daniel Lager
Förderung
- Innovative Medicines Initiative 2 Joint Undertaking
- European Union's Horizon 2020 Research and Innovation Programme and EFPIA
Zitieren
APA
Mutter, N., Posch, B., Gillitschka, Y., Kataeva, N., Michalek, B., Lager, D., Staniszewski, F., Schilder, A., Osinkina, L., Westenthanner, M., Stehr, J., Buersgens, F., & Peham, J. R. (2025). Lyophilised Reverse Transcriptase and Polymerase for Point‐of‐Care Diagnostics of SARS ‐ CoV ‐2. Microbial Biotechnology, 18(7). https://doi.org/10.1111/1751-7915.70200
Vancouver
Mutter N, Posch B, Gillitschka Y, Kataeva N, Michalek B, Lager D, et al. Lyophilised Reverse Transcriptase and Polymerase for Point‐of‐Care Diagnostics of SARS ‐ CoV ‐2. Microbial Biotechnology. 2025;18(7). doi:10.1111/1751-7915.70200
BibTeX
@article{Mutter2025,
author = {Mutter, Natalie and Posch, Barbara and Gillitschka, Yasmin and Kataeva, Nadezhda and Michalek, Birgit and Lager, Daniel and Staniszewski, Filip and Schilder, Alexandra and Osinkina, Lidiya and Westenthanner, Maximilian and Stehr, Joachim and Buersgens, Federico and Peham, Johannes R},
title = {Lyophilised Reverse Transcriptase and Polymerase for Point‐of‐Care Diagnostics of SARS ‐ CoV ‐2},
journal = {Microbial Biotechnology},
year = {2025},
volume = {18},
number = {7},
doi = {10.1111/1751-7915.70200}
}
EUVIMED